ExploreWatchlistsPricing
  1. JP-listed companies
  2. RIBOMIC Inc.
  3. Financials
  4. Provision for income taxes

RIBOMIC Inc. (4591)

Market cap
¥2.9B
P/E ratio
-2.1x
Ribomics develops next-generation aptamer drugs using its proprietary RiboART System to treat unmet medical needs like achondroplasia and eye diseases.
SummaryFinancialsDividendsHistoryOwnershipWorkforce
Period EndProvision for income taxes (Million JPY)YoY (%)
Mar 31, 20261+0.00%
Mar 31, 20251+0.00%
Mar 31, 20241+0.00%
Mar 31, 20231+0.00%
Mar 31, 20221+0.00%
Mar 31, 20211+0.00%
Mar 31, 20201+0.00%
Mar 31, 20191+0.00%
Mar 31, 20181+0.00%
Mar 31, 20171+0.00%
Mar 31, 20161-10.24%
Mar 31, 20151

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)
AI Chat